RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL)
In a report released yesterday, Leonid Timashev from RBC Capital maintained a Hold rating on Exelixis, with a price target of $43.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Timashev is a 5-star analyst with an average return of 18.2% and a 52.72% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and BeOne Medicines.
In addition to RBC Capital, Exelixis also received a Hold from Morgan Stanley’s Sean Laaman in a report issued today. However, on the same day, William Blair reiterated a Buy rating on Exelixis (NASDAQ: EXEL).
Based on Exelixis’ latest earnings release for the quarter ending January 2, the company reported a quarterly revenue of $598.66 million and a net profit of $244.53 million. In comparison, last year the company earned a revenue of $566.76 million and had a net profit of $139.86 million
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Last month, Aftab Dana, the EVP, Research and Development of EXEL sold 47,918.00 shares for a total of $2,132,351.00.
Read More on EXEL:
Disclaimer & DisclosureReport an Issue
- Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
- Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
- Exelixis: Solid Financial Beat and Advancing Oncology Pipeline Drive Upgraded Earnings Outlook and $54 Price Target
- Exelixis price target raised to $54 from $52 at H.C. Wainwright
- Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
